State of Alaska Department of Revenue reduced its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 1.3% ...

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...

Sarepta Therapeutics ... in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed ...

Indicated for patients with a confirmed mutation of the dystrophin gene amenable to exon 51 skipping, the drug could be used in around 13% of the disease population. Sarepta’s share price almost ...

Part 1 patients sustained a +2.88 NSAA improvement two years post-treatment with consistent micro-dystrophin expression ... agreement signed in 2019, Sarepta is working with Roche Holdings ...

Sarepta (SRPT) announced topline results from ... dosing showed consistent and sustained expression of Elevidys micro-dystrophin compared to week 12 biopsies, as measured by western blot, and ...

Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is ...

Roche and Sarepta Therapeutics have shared positive top-line results ... condition caused by a change or mutation in the gene that encodes instructions for dystrophin, which is required to strengthen ...

Elevidys, a product developed by Sarepta Therapeutics Inc., scrupulously treats Duchenne muscular dystrophy DMD by delivering a micro-dystrophin gene to muscle cells, partially restoring ...

In 2019, Roche entered into a global collaboration agreement with Sarepta Therapeutics ... phase Ib study assessing Elevidys micro-dystrophin protein expression and safety of Elevidys in seven cohorts ...